Skip to content
CharitiesAidWelfare, Medical Health Aged Care

Bowel cancer screening eligibility now 45

Bowel Cancer Australia 2 mins read

Bowel cancer screening eligibility now 45

People aged 45-49 now eligible to request a free screening test as announced in 2024-25 Federal Budget

 

  • Over 1.6 million Australians aged 45-49 are now eligible to participate in the National Bowel Cancer Screening Program (NBCSP) on an opt-in basis.
  • Since 2018, Bowel Cancer Australia has advocated for screening from age 45.
  • People aged 40-49 account for 56% of new cases and 64% of deaths in those diagnosed under 50.

 

Wednesday 15 May, Sydney: Bowel Cancer Australia has welcomed another milestone in its 6-year campaign, with the Australian Government lowering eligibility for bowel cancer screening from age 50 to 45, as announced in the Federal Budget.

 

From 1 July 2024, an additional 1.6 million Australians aged 45-49 will be eligible to request a screening test from the National Bowel Cancer Screening Program. Once a person aged 45-49 opts-in to the Program, they will receive a screening test every two years.

 

Over the past three decades, bowel cancer rates have been increasing in people under age 50, both in Australia and globally.

 

1,716 Australians are diagnosed with early-onset bowel cancer each year, with people aged 40-49 accounting for 56 percent of new cases and 64 percent of deaths in those diagnosed under 50.

 

Bowel Cancer Australia CEO Julien Wiggins said: “We have been advocating tirelessly for the lowering of the screening age in response to the increasing rates of bowel cancer in younger people.”

 

We thank our dedicated and passionate advocates for their ongoing support of our campaign, along with members of the recently established Parliamentary Friends of Bowel Cancer.”

 

The Budget announcement follows updated clinical practice guidelines recommending a lowering of the bowel cancer screening start age which were endorsed by the National Health and Medical Research Council (NHMRC) in October 2023.

 

The updated clinical practice guidelines also recommend people aged 40-44 can request screening via their healthcare professional prior to receiving their first NBCSP invitation.


Contact details:


For an interview with a medical expert or patient contact:
Stephanie Bansemer-Brown – Bowel Cancer Australia
stephanie@bowelcanceraustralia.org   |   0412 915 797

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • CharitiesAidWelfare, Government VIC
  • 31/10/2024
  • 14:04
Council to Homeless Persons

Victorians waiting longer for homes as public wait times surge

Victoria’s public housing waiting times have blown out to an average of almost 20 months for people who have been assessed as a high priority. New figures released today in the Department of Families, Fairness and Housing annual report show average wait times in 2023/24 increased to 19.8 months for people with priority access. That is 88 per cent longer than the Victorian government’s own target of 10.5 months, and a 30 per cent increase from two years ago. Council to Homeless Persons has warned the state’s dire shortage of social housing is behind the soaring wait times, which are…

  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.